Trials / Completed

CompletedNCT00605410

Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 12 (actual)

Sponsor: University of Saskatchewan · Academic / Other
Sex: All
Age: 19 Years
Healthy volunteers: Not accepted

Summary

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Conditions

Asthma

Interventions

Type	Name	Description
DRUG	ipratropium bromide	2 puffs (40 micrograms) 2 puffs (0micrograms)
DRUG	placebo	Matched placebo

Timeline

Start date: 2008-01-01
Primary completion: 2008-04-01
Completion: 2008-04-01
First posted: 2008-01-31
Last updated: 2009-01-07

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00605410. Inclusion in this directory is not an endorsement.